Abstract Each year, about 5–6 cases out of 100,000 people are diagnosed with primary
malignant brain tumors, of which about 80% are malignant gliomas (MGs). Glioblastoma …

Glioblastoma (GBM) is a primary neuroepithelial tumor of the central nervous system,
characterized by an extremely aggressive clinical phenotype. Patients with GBM have a …

Glioblastoma (GBM) is a highly malignant brain tumor characterized by a heterogeneous
population of genetically unstable and highly infiltrative cells that are resistant to …

Malignant gliomas, the most common type of primary brain tumor in adults, are associated
with disproportionate cancer-related morbidity and mortality. Recently, there have been …

Malignant astrocytic gliomas such as glioblastoma are the most common and lethal
intracranial tumors. These cancers exhibit a relentless malignant progression characterized …

Polymeric nanoparticles have tremendous potential to improve the efficacy of therapeutic
cancer treatments by facilitating targeted delivery to a desired site. The physical and …

Malignant gliomas such as glioblastoma multiforme (GBM) present some of the greatest
challenges in the management of cancer patients worldwide, despite notable recent …

Recent studies have demonstrated the utility and superiority of long non-coding RNAs
(lncRNAs) as novel biomarkers for cancer diagnosis, prognosis, and therapy. In the present …

Background: Glioblastoma multiforme (GBM) is the most common and lethal primary
malignancy of the central nervous system (CNS). Despite the proven benefit of surgical …

Purpose Cilengitide, an inhibitor of αvβ3 and αvβ5 integrin receptors, demonstrated minimal
toxicity and durable activity across a wide range of doses administered to adults with …